Last Updated on January 21, 2022 by Neelam Singh
Quick Take
A social media post claims Japan is opting for Ivermectin for treating Covid. We fact checked and found this claim to be False.
The Claim
A social media post claims ‘Instead of being insane, Japan opted for Ivermectin and a return to freedom, and it’s paid off.’ The post can be found here.
Fact Check
What is Ivermectin?
Ivermectin is an approved drug by the U.S. Federal Drug Administration for treating parasites in animals and humans and treating head lice and skin conditions like rosacea.
Can Ivermectin be used for treating Covid-19?
Ivermectin has not been approved by medical authority body for treatment of COVID-19.
FDA has repeatedly warned against using it for COVID-19. Currently available data do not show ivermectin is effective against COVID-19.
The Indian Govt had initially included the drug in Covid treatment protocol but later decided to drop it from a revised guideline.
Clinical trials assessing ivermectin tablets for the prevention or treatment of COVID-19 in people are ongoing.
Has Japan approved Ivermectin to treat Covid-19 ?
Till date, Ivermectin is not listed as approved to treat or prevent COVID-19 in Japan by the country’s medicines regulator, the Pharmaceuticals and Medical Devices Agency (PMDA). Ivermectin is also not mentioned in the public guidance on COVID-19 from Japan’s Ministry of Health, Labour and Welfare.
It is also not true that Japan has beaten the COVID successfully using Ivermectin. In fact, as per data in WHO website, the number of COVID infected patients have seen a steady increase in Japan.
Disclaimer: Medical Science is an ever evolving field. We strive to keep this page updated. In case you notice any discrepancy in the content, please inform us at [email protected]. You can futher read our Correction Policy here. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website or it's social media channels. Read our Full Disclaimer Here for further information.
